OpenAlex
PricingAboutJobs
Log inGet started
Work

A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride (LY335979), Administered Intravenously in Combination with Doxorubicin in Patients with Advanced Malignancy

HTML

Year: 2004
Type: article
Study design: Clinical Trial
Source: Clinical Cancer Research
DOI: 10.1158/1078-0432.ccr-03-0644
Authors: Alan Sandler, Michael Gordon, Dinesh P. de Alwis, Isabelle Pouliquen, Lisa Green, Phil Marder, Ajai Chaudhary, Karen Fife, Linda Battiato, Christopher Sweeney, Christopher Jordan, Michael Burgess, Christopher A. Slapak
Institutions: Indiana University Indianapolis, Indiana University School of Medicine, Eli Lilly (United States)
Language: English

Topic: Drug Transport and Resistance Mechanisms
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: zosuquidar, P-glycoprotein inhibition, doxorubicin, advanced cancer, pharmacokinetics, drug-drug interactions, natural killer cells, dose-limiting toxicity, leukopenia, thrombocytopenia
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2141777108
FWCI: 7.719
Cites: 28
Cited by: 168
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security